Speaker
Description
ABSTRACT : Life-long treatment with Carbamazepine (CBZ) and Valproate (VAP) may change metabolic pathway by affecting
the hepatic enzyme system leading to increase vascular and cardiovascular risk in epileptic patients, so this study evaluate the
effect of enzyme inducer CBZ, enzyme inhibitor VAP and non-enzyme inducer Lamotrigine (LTG) antiepileptic drugs on
serologic biomarkers and evaluate effect of prolong duration of treatment with increasing vascular risk.Ninety epileptic
patients who were receiving Anti-epileptic monotherapy including enzyme inducer CBZ, enzyme inhibitor VAP and non-enzyme
inducer LTG for more than 2 years and 30 healthy individual considered as control enrolled in this study. All subject information
such as age, sex, Body mass index, duration of disease and treatmentwere recorded by using a questionnaire form. Laboratory
investigations of serum FBS, UA, lipid profile, CRP and ESR were done to all participant in the study.Prolong treatment with
CBZ monotherapy associated with increased level of serum total cholesterol, LDL-C,CRP and ESR level with P-value < 0.001.
While prolong treatment with VAP monotherapy associated with significant higher level of serum UA than the other groups
with P-value < 0.001 and also increase level of CRP and ESR than LTG and control groups with P-value < 0.05 , in addition LTG
increase level of serum UA than control with P-value < 0.05. Also regression analysis show weak positive correlation between
duration of treatment and vascular biomarkers. Epileptic patients with CBZ and VAP exhibit alteration in vascular biomarkers
that may associate with increased risk of cardiovascular disease, in addition increase duration of treatment may increase risk
of atherosclerosis.
| Has the manuscript been published? | Published |
|---|---|
| Field/discipline | Pharmacology & Toxicology |
| Intend to be published in the conference journal (IJPS)? | No |
